Ventripoint Issues Shares for Payment of Debenture Interest

Executive Summary

• Ventripoint Diagnostics Ltd. has issued 555,699 common shares to settle $61,217 in interest owing on existing convertible debentures.
• The issuance was conducted following approval from the TSX Venture Exchange.
• The transaction includes a related party component, with insiders receiving a portion of the newly issued shares.

Key Details

• Shares Issued: 555,699 common shares.
• Purpose of Issuance: Payment of an aggregate of $61,217 in interest owing on outstanding Convertible Debentures (originally issued on September 20, 2024; March 21, 2025; September 2, 2025; and October 14, 2025).
• Debenture Terms: 10% per annum interest rate, payable every 6 months.
• Share Price: Deemed price of $0.11 per share.
• Hold Period: Subject to a hold period of 4 months and one day.
• Related Party Transaction: Certain insiders of the Corporation received an aggregate of 15,778 shares.
• Regulatory Compliance: The transaction is a related party transaction under TSXV Policy 5.9 and MI-61-101; the Corporation is relying on specific valuation and minority shareholder approval exemptions.